Last reviewed · How we verify
Risperidone and Zotepine for delirium
Risperidone and Zotepine for delirium is a Atypical antipsychotic combination Small molecule drug developed by Changhua Christian Hospital. It is currently FDA-approved for Delirium (acute confusion and agitation in hospitalized patients). Also known as: risperidone( Risperdal), zotepine( Lodopine).
Risperidone and zotepine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce agitation, hallucinations, and delirium symptoms.
Risperidone and zotepine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce agitation, hallucinations, and delirium symptoms. Used for Delirium (acute confusion and agitation in hospitalized patients).
At a glance
| Generic name | Risperidone and Zotepine for delirium |
|---|---|
| Also known as | risperidone( Risperdal), zotepine( Lodopine) |
| Sponsor | Changhua Christian Hospital |
| Drug class | Atypical antipsychotic combination |
| Target | Dopamine D2 receptor, serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Both agents are second-generation antipsychotics that antagonize dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing psychotic symptoms and agitation. Zotepine additionally has potent 5-HT2A antagonism and noradrenergic activity, while risperidone's serotonergic blockade contributes to mood stabilization. This combination approach targets multiple neurotransmitter systems implicated in delirium pathophysiology.
Approved indications
- Delirium (acute confusion and agitation in hospitalized patients)
Common side effects
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Sedation
- Orthostatic hypotension
- Weight gain
- Metabolic syndrome risk
- QT prolongation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidone and Zotepine for delirium CI brief — competitive landscape report
- Risperidone and Zotepine for delirium updates RSS · CI watch RSS
- Changhua Christian Hospital portfolio CI
Frequently asked questions about Risperidone and Zotepine for delirium
What is Risperidone and Zotepine for delirium?
How does Risperidone and Zotepine for delirium work?
What is Risperidone and Zotepine for delirium used for?
Who makes Risperidone and Zotepine for delirium?
Is Risperidone and Zotepine for delirium also known as anything else?
What drug class is Risperidone and Zotepine for delirium in?
What development phase is Risperidone and Zotepine for delirium in?
What are the side effects of Risperidone and Zotepine for delirium?
What does Risperidone and Zotepine for delirium target?
Related
- Drug class: All Atypical antipsychotic combination drugs
- Target: All drugs targeting Dopamine D2 receptor, serotonin 5-HT2A receptor
- Manufacturer: Changhua Christian Hospital — full pipeline
- Therapeutic area: All drugs in Psychiatry / Neurology
- Indication: Drugs for Delirium (acute confusion and agitation in hospitalized patients)
- Also known as: risperidone( Risperdal), zotepine( Lodopine)
- Compare: Risperidone and Zotepine for delirium vs similar drugs
- Pricing: Risperidone and Zotepine for delirium cost, discount & access